H. Lundbeck A/S (HLBBF)
OTCMKTS · Delayed Price · Currency is USD
7.21
-0.29 (-3.87%)
At close: Sep 30, 2025
H. Lundbeck Employees
H. Lundbeck had 5,707 employees as of December 31, 2024. The number of employees increased by 26 or 0.46% compared to the previous year.
Employees
5,707
Change (1Y)
26
Growth (1Y)
0.46%
Revenue / Employee
$649,641
Profits / Employee
$96,254
Market Cap
6.78B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 5,707 | 26 | 0.46% |
Dec 31, 2023 | 5,681 | 231 | 4.24% |
Dec 31, 2022 | 5,450 | 102 | 1.91% |
Dec 31, 2021 | 5,348 | -280 | -4.98% |
Dec 31, 2020 | 5,628 | -178 | -3.07% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
Glass House Brands | 374 |
Elite Pharmaceuticals | 68 |
Northwest Biotherapeutics | 25 |
CytoDyn | 13 |
American Oncology Network | 1,914 |
Silence Therapeutics | 116 |
Jushi Holdings | 1,234 |
Nuo Therapeutics | 9 |
H. Lundbeck News
- 5 weeks ago - Lundbeck showcases new clinical migraine data, including long-term preventive effectiveness of Vyepti® (eptinezumab) in patients severely impacted by migraine - Benzinga
- 4 months ago - New data demonstrates robust efficacy of Vyepti® (eptinezumab) in otherwise difficult-to-treat patients with severe migraine - Benzinga
- 4 months ago - New data from phase III trial confirms efficacy of Vyepti® (eptinezumab) in Asian population with chronic migraine - Benzinga
- 5 months ago - Lundbeck Delivering On The Financials, But Needs Some Positive Clinical Drivers - Seeking Alpha
- 7 months ago - Lundbeck's potential treatment for Multiple System Atrophy granted Orphan Drug Designation in Japan - PRNewsWire
- 9 months ago - Lundbeck's Appreciation Potential Is Closely Tied To A High-Risk Clinical Pipeline (Rating Upgrade) - Seeking Alpha
- 1 year ago - Longboard Pharmaceuticals HSR waiting period expires for Lundbeck deal - Seeking Alpha
- 1 year ago - Longboard Pharma's Lucrative Exit To Lundbeck Another Coup For Management - Seeking Alpha